Cytokinetics, Incorporated — Company profile
Healthcare · Biotechnology · United States
Last price 63.31 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 8.80B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Cytokinetics, Incorporated, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel muscle activators and muscle inhibitors as potential treatments for debilitating diseases in the United States. The company markets MYQORZO, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of symptomatic oHCM. It also develops Aficamten, a novel, oral, and small molecule cardiac myosin inhibitor for the treatment of HCM; and omecamtiv mecarbil, a potential treatment across the continuum of care in heart failure with severely reduced ejection fraction. In addition, the company is involved in developing and Ulacamten, a novel, selective, oral, and small molecule cardiac myosin inhibitor designed to reduce the hypercontractility associated with heart failure with preserved ejection fraction in Phase 1 clinical trials; and CK-089, a fast skeletal muscle troponin activator in Phase 1 clinical trials. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Details
| Name | Cytokinetics, Incorporated |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 673 |
| Founded | 1997 |
| Ipo Date | 2004-04-29 |
| Ceo | Robert Blum |
| Country | United States |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| Isin | US23282W6057 |
| Cusip | 23282W605 |
| Cik | 0001061983 |
| Sic | 2834 |
| Stock Type | Common Stock |
Key executives
| Name | Title |
|---|---|
| Robert I. Blum | Chief Executive Officer, President and Director |
| Sung H. Lee | Executive Vice President and Chief Financial Officer |
| Jeffrey J. Hessekiel J.D. | Executive Vice President, Chief Legal and Administrative Officer |
| Dr. Fady Ibraham Malik FACC, M.D., Ph.D. | Executive Vice President of Research and Development |
| Andrew M. Callos | Executive Vice President and Chief Commercial Officer |
| Dr. James H. Sabry M.D., Ph.D. | Co-Founder and Chairman of Scientific Advisory Board |
| Dr. James A. Spudich Ph.D. | Co-Founder and Member of Scientific Advisory Board |
| Holly Laughlin | Vice President of Accounting and Corporate Controller |
| Steven M. Cook J.D. | Senior Vice President of Global Supply Chain Operations and Technical Operations |
| Scott R. Jordan | Senior Vice President of Global Marketing and Commercial Strategy |
Contact
| Address | 350 Oyster Point Boulevard, South San Francisco, California 94080, United States |
| Phone | 650 624 3000 |
| Website | https://www.cytokinetics.com |